Humacyte (NASDAQ:HUMA) shares climbed ~57% in the premarket on Friday after the bioengineered tissue maker announced the FDA approval of Symvess, an off-the-shelf, implantable vascular conduit indicated for arterial injury.

According to the FDA labeling, Symvess will be available for adults